Traws Pharma Inc (TRAW) Hedge Fund Ownership (Q2 2026)

Q: Is it too late to buy Traws Pharma Inc (TRAW) following the 2026 Q2 hedge fund 13F filings?

As of today, TRAW has moved -7.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +4.3% for the XLV sector ETF — an outperformance of -11.3%. Since the quarter end (June 30, 2026), TRAW gained -37.2% vs +10.1% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Traws Pharma Inc (TRAW)

33 + Investors. Track Smart Money conviction in TRAW. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — TRAW

Based on 33 hedge funds · latest filing: 2026 Q2 · updated quarterly

📈

Buying streak — 3 quarters in a row

last 6Q

For 3 consecutive quarters, more hedge funds added TRAW than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

🏔️

At the ownership peak (100% of max)

100% of all-time peak

33 hedge funds hold TRAW right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.

🚀

Fast accumulation — +74% more funds vs a year ago

fund count last 6Q

+14 new funds entered over the past year (+74% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.

🟢

More buyers than sellers — 61% buying

22 buying14 selling

Last quarter: 22 funds were net buyers (13 opened a brand new position + 9 added to an existing one). Only 14 were sellers (8 trimmed + 6 sold completely). A clear majority buying is a strong confirmation signal.

➡️

Steady new buyers — ~13 new funds per quarter

new funds entering per quarter

Funds opening this position for the first time: 3 → 8 → 13 → 13. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.

🔄

Mostly new holders — 64% entered in last year

■ 0% conviction (2yr+) ■ 36% medium ■ 64% new

Only 0 funds (0%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

💎

Buying through price weakness — shares +70%, value -22%

Value

-22%

+70%

Last quarter: funds added +70% more shares while total portfolio value only changed -22%. Institutions were buying while the price was falling — a high-conviction accumulation signal. They're deliberately loading up on the dip.

📈

Growing discovery — still being found

4 → 3 → 8 → 13 → 13 new funds/Q

New funds entering each quarter: 3 → 8 → 13 → 13. A growing number of institutions are discovering TRAW each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.

🌱

Early stage — 64% of holders entered in last year

■ 0% veterans ■ 36% 1-2yr ■ 64% new

Of 33 current holders: 21 (64%) entered in the past year, only 0 (0%) are 2+ year veterans. This is an early-phase institutional idea — still being discovered. High upside potential if the thesis plays out, but thin conviction base.

📋

Smaller funds dominant — 3% AUM from top-100

3% from top-100 AUM funds

9 of 33 holders rank in the top 100 by AUM, but together hold only 3% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

5.6

out of 10

Moderate Exit Risk

Exit risk score 5.6/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q2)	Prior (2026 Q1)	Change
Funds Holding	33	26	26.92%
13F Shares	6M	4M	70.08%
Total Value	$5M	$7M	-21.98%
New Positions	13	13	-
Increased Positions	9	2	+7
Closed Positions	6	8	-2
Reduced Positions	8	4	+4
Total Calls	0	0	-
Total Puts	0	0	-
PUT/CALL Ratio	0.0	0.0	Bullish

Metric

All 13F Filers (2026 Q2)

Prior (2026 Q1)

Change

Funds Holding

26.92%

13F Shares

70.08%

Total Value

$5M

$7M

-21.98%

New Positions

Increased Positions

Closed Positions

-2

Reduced Positions

Total Calls

Total Puts

PUT/CALL Ratio

0.0

Bullish

Institutional Holders (2026 Q2)

33 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in TRAW. Verified SEC 13F-HR filings.

QUARTER:

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 TRAW holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Ally Bridge Group (NY) LLC	0.59%	786,236	$663K
2	Lynx1 Capital Management LP	0.09%	559,470	$472K
3	Dauntless Investment Group, LLC	0.05%	80,574	$68K
4	Sphera Funds Management LTD.	0.04%	398,486	$336K
5	Ikarian Capital, LLC	0.04%	478,142	$403K
6	ADAR1 Capital Management, LLC	0.02%	597,729	$504K
7	Orbimed Advisors LLC	0.02%	1,203,260	$1.0M
8	Kynam Capital Management, LP	0.00%	84,400	$71K
9	Boothbay Fund Management, LLC	0.00%	133,936	$113K
10	Adage Capital Partners GP, L.L.C.	0.00%	730,000	$616K
11	Alyeska Investment Group, L.P.	0.00%	164,376	$139K
12	XTX Topco Ltd	0.00%	18,092	$15K
13	Hrt Financial LP	0.00%	91,220	$76K
14	Tower Research Capital LLC (TRC)	0.00%	5,142	$4K
15	SBI Securities Co., Ltd.	0.00%	1,721	$1K
16	Huntington National Bank	0.00%	4,676	$4K
17	Jane Street Group, LLC	0.00%	216,006	$182K
18	Vanguard Fiduciary Trust Co	0.00%	54,511	$46K
19	Vanguard Capital Management LLC	0.00%	330,049	$278K
20	Federation des caisses Desjardins du Quebec	0.00%	500	—
21	UBS Group AG	0.00%	3,451	$3K
22	Barclays plc	0.00%	1,947	$2K
23	BlackRock, Inc.	0.00%	9,941	$8K
24	Cassaday & Co Wealth Management LLC	0.00%	6	—
25	Morgan Stanley	0.00%	468	—

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Traws Pharma Inc (TRAW)

What does the Smart Money Trend signal show for TRAW?

Buying streak — 3 quarters in a row: For 3 consecutive quarters, more hedge funds added TRAW than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for TRAW?

More buyers than sellers — 61% buying: Last quarter: 22 funds were net buyers (13 opened a brand new position + 9 added to an existing one). Only 14 were sellers (8 trimmed + 6 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for TRAW holders?

Smaller funds dominant — 3% AUM from top-100: 9 of 33 holders rank in the top 100 by AUM, but together hold only 3% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

How long have hedge funds held TRAW?

Mostly new holders — 64% entered in last year: Only 0 funds (0%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

Is it too late to buy Traws Pharma Inc (TRAW) following the 2026 Q2 hedge fund 13F filings?

As of today, TRAW has moved -7.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +4.3% for the XLV sector ETF — an outperformance of -11.3%. Since the quarter end (June 30, 2026), TRAW has gained -37.2% vs +10.1% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Traws Pharma Inc (TRAW)

Smart Money Signals — TRAW

Buying streak — 3 quarters in a row

At the ownership peak (100% of max)

Fast accumulation — +74% more funds vs a year ago

More buyers than sellers — 61% buying

Steady new buyers — ~13 new funds per quarter

Mostly new holders — 64% entered in last year

Buying through price weakness — shares +70%, value -22%

Growing discovery — still being found

Early stage — 64% of holders entered in last year

Smaller funds dominant — 3% AUM from top-100

Institutional Sentiment Summary — TRAW

Hedge Fund Ownership: TRAW

Market Analysis: TRAW

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: TRAW

Is It Too Late to Buy Traws Pharma Inc (TRAW) Based on Hedge Fund 13F Filings?

Hedge Fund Positioning: TRAW

Statistics: TRAW

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q2)

Frequently Asked Questions — Traws Pharma Inc (TRAW)

Welcome to 13Foresight!